Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04085809 · ClinicalTrials.gov registry record · NA
This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides on Dry Skin in Healthy Female Volunteers. AmLactin® Rapid Relief is an Over-the-counter Cosmetic
A NA study of Dry Skin, sponsored by Sandoz.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT04085809 is a NA study of Dry Skin that has completed, run by Sandoz. The registered enrollment target is 56 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04085809, a NA study of Dry Skin, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study was to investigate if AmLactin® Rapid Relief improves the skin through desquamation and moisturization via D-SQUAME analysis. AmLactin® Rapid Relief is an over-the-counter cosmetic.
Conditions Studied
Interventions
- OTHER AmLactin® Rapid Relief
Study Locations (1)
North Carolina
- Sandoz Investigational Site - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2019-04-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04085809
The ClinicalTrials.gov registry entry for NCT04085809 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sandoz, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Skin appearing as the primary indexed condition, and to 1 intervention - of which AmLactin® Rapid Relief is the first listed.
NCT04085809 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04085809 about?
NCT04085809 is a clinical study titled "This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides on Dry Skin in Healthy Female Volunteers. AmLactin® Rapid Relief is an Over-the-counter Cosmetic". The primary objective of this study was to investigate if AmLactin® Rapid Relief improves the skin through desquamation and moisturization via D-SQUAME analysis. AmLactin® Rapid Relief is an over-the-counter cosmetic.
What is the current status of trial NCT04085809?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2019-03-26. Estimated completion is 2019-04-08.
What conditions does trial NCT04085809 study?
This clinical trial studies the following conditions: Dry Skin.
What interventions are being tested in trial NCT04085809?
The interventions under investigation include: AmLactin® Rapid Relief (OTHER).
Who is sponsoring clinical trial NCT04085809?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04085809 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Skin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.